Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 42.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,417 shares of the company’s stock after selling 19,869 shares during the period. Edgestream Partners L.P.’s holdings in Moderna were worth $1,098,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the last quarter. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna during the 4th quarter worth approximately $37,000. Larson Financial Group LLC increased its position in Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its position in Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after buying an additional 778 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Down 6.1 %

Shares of NASDAQ MRNA opened at $33.76 on Wednesday. The stock has a market capitalization of $13.03 billion, a P/E ratio of -3.64 and a beta of 1.86. The stock’s 50 day moving average price is $36.38 and its two-hundred day moving average price is $48.11. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MRNA. Bank of America lowered their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Berenberg Bank increased their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a research report on Friday, February 14th. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, Morgan Stanley dropped their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.